Zalifrelimab

Names

[ Name ]:
Zalifrelimab

Biological Activity

[Description]:

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Zalifrelimab（AGEN1884；0.1、1、10 或 100 μg/mL）有效增强抗原特异性 T 细胞反应性，可与其他免疫调节抗体联合使用。Zalifrelimab 与 PD-1 阻断剂有效结合，可在外周引起 T 细胞增殖反应[2]。

[In Vivo]

Zalifrelimab（AGEN1884；10 mg/kg；静脉注射；第 1 天和第 29 天）在非人灵长类动物中具有良好的耐受性，可增强疫苗介导的抗原特异性免疫[2]。 Animal Model: Cynomolgus macaques (Macaca fascicularis)[2] Dosage: 10 mg/kg Administration: i.v.; on days 1 and 29 Result: Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo.

[References]

[1]. David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.

[2]. Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.